Abstract:BACKGROUND: There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120) were evaluated.METHODS: The recombinant Ad4 vectors were generated with a full deletion of the E3 region of Ad4 to accommodate the env gene sequences. The vaccine candidates were assessed in vitro following infection of A549 cells for Env-specific protein expression and for posttranslational transport to the cell surface as monitored by the binding of broadly neutralizing antibodies (bNAbs). The capacity of the Ad4Env vaccines to induce humoral immunity was evaluated in rabbits for Env gp140 and V1V2-specific binding antibodies, and HIV-1 pseudovirus neutralization. Mice immunized with the Ad4Env160 vaccine were assessed for IFNγ T cell responses specific for overlapping Env peptide sets.RESULTS: Robust Env protein expression was confirmed by western blot analysis and recognition of cell surface Env gp160 by multiple bNAbs. Ad4Env vaccines induced humoral immune responses in rabbits that recognized Env 1086 gp140 and V1V2 polypeptide sequences derived from 1086 clade C, A244 clade AE, and gp70 V1V2 CASE A2 clade B fusion protein. The immune sera efficiently neutralized tier 1 clade C pseudovirus MW965.26 and neutralized the homologous and heterologous tier 2 pseudoviruses to a lesser extent. Env-specific T cell responses were also induced in mice following Ad4Env160 vector immunization.CONCLUSIONS: The Ad4Env vaccine vectors express high levels of Env glycoprotein and induce both Env-specific humoral and cellular immunity thus supporting further development of this new Ad4 HIV-1 Env vaccine platform in Phase 1 clinical trials.

[Immunogenicity of Plasmid DNA and Adenoviral Vectors Encoding HIV-1 Subtype B Env Gene].

Immunogenicity of DNA Vaccines Encoding Structural Proteins and Regulatory/accessory Proteins Derived from an HIV-1 CRF01_AE Isolate Circulating in China

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B｀/C and A/E recombinant HIV-1 strains

[Immune Response Induced by HIV DNA Vaccine Combined with Recombinant Adeno-Associated Virus].

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C

Construction and Immunogenicity Analysis of a Vaccine Against HIV-1 AE Recombinant

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Immunogenicity of DNA Vaccines Encoding Regulatory/accessory Proteins Derived from Three Different Prevalent Strains in China

Combined immunization of mice with DNA, rMVA and rAd5 expressing HIV-1 structural genes from different subtypes.

Immunogenicity Comparison Between Codon Optimized HIV-1 CRF BC_07 Gp140 and Gp145 Vaccines.

[Immunogenicity of Recombinant Adeno-Asscociated Virus Type 1 Expressing HIV-1 Gp120 Gene in Mice and Rhesus Macaques].

[Construction and Identification of Recombinant Adenoviral Vector Encoding B7-H4 Gene].

Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140

[Construction and Immunological Evaluation of Recombinant Adenovirus Containing Codon-Modified HPV 16 L1 Gene].

Expression and Identification of Immunological Activities of the HIV‐gp120N‐Human Interferon Gamma Fusion Protein

Construction and Immunology of HIV-2 Gp105 and / or Gag DNA Vaccine

Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial

Construction and Expression of a Recombinant Adenovirus Encoding E6-E7 Fusion Proteins of Hmnan Papillomavirus Subtypes 16, 18, and 58

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Enhancement of Primary and Secondary Cellular Immune Responses Against Human Immunodeficiency Virus Type 1 Gag by Using DNA Expression Vectors That Target Gag Antigen to the Secretory Pathway